BioLineRx begins new BL-1020 study
Israeli drug developer BioLineRx has initiated a study designed to determine the clinical binding properties of BL-1020, a developmental antipsychotic. Specifically, this will evaluate the agent's interaction with dopamine receptors in the brain.
The program, which is being conducted after the drug was successfully filed with the US Food and Drug Administration (Marketletter February 19), is a single-center, randomized, open label, sequential cohort study, and is intended to provide further confirmation of earlier efficacy findings. The firm added that the resulting data will form the basis of a Phase II dose-finding assessment, which is scheduled for the end of June.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze